I 
Insulet PODD · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
149.81
+2.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$2.71bn
FY2016FY2025
Net income
$247.1m
FY2016FY2025
Free cash flow
$377.7m
FY2016FY2025
Shareholders' equity
$1.52bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.71bn | $2.07bn | $1.70bn | $1.31bn | $1.10bn | $904.4m | $738.2m | $563.8m | $463.8m | $367.0m |
| Gross profit | $1.94bn | $1.45bn | $1.16bn | $805.6m | $752.1m | $582.3m | $480.3m | $370.2m | $277.2m | $211.1m |
| Research and development | $301.1m | $219.6m | $205.0m | $180.2m | $160.1m | $146.8m | $132.3m | $88.6m | $74.5m | $55.7m |
| Operating income | $473.8m | $308.9m | $220.0m | $36.5m | $81.7m | $54.8m | $50.0m | $27.4m | −$7.4m | −$12.4m |
| Net income | $247.1m | $418.3m | $206.3m | $4.6m | $16.8m | $6.8m | $11.6m | $3.3m | −$26.8m | −$28.9m |
| Diluted earnings per share | 3.50 | 5.65 | 2.95 | 0.07 | 0.24 | 0.10 | 0.18 | 0.05 | -0.46 | -0.50 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.19bn | $3.09bn | $2.59bn | $2.25bn | $2.05bn | $1.87bn | $1.14bn | $928.7m | $816.7m | $456.6m |
| Cash and short-term investments | $716.1m | $953.4m | $704.2m | $674.7m | $791.6m | $947.6m | $376.1m | $288.9m | $440.1m | $298.6m |
| Total liabilities | $1.68bn | $1.88bn | $1.86bn | $1.77bn | $1.49bn | $1.27bn | $1.07bn | $716.6m | $658.2m | $393.5m |
| Debt | $949.2m | $1.39bn | $1.42bn | $1.40bn | $1.27bn | $1.06bn | $887.9m | $592.0m | $566.2m | $333.0m |
| Shareholders' equity | $1.52bn | $1.21bn | $732.7m | $476.4m | $556.3m | $603.6m | $75.9m | $212.1m | $158.5m | $63.1m |
| Shares outstanding | 71m | 74m | 70m | 70m | 70m | 66m | 64m | 61m | 58m | 57m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $569.3m | $430.3m | $145.7m | $119.0m | −$68.1m | $84.0m | $98.4m | $35.9m | $41.3m | $15.9m |
| Capital spending | −$191.6m | −$124.9m | −$75.6m | −$157.3m | −$122.7m | −$166.5m | −$170.9m | −$162.4m | −$77.2m | −$22.1m |
| Free cash flow | $377.7m | $305.4m | $70.1m | −$38.3m | −$190.8m | −$82.5m | −$72.5m | −$126.5m | −$35.9m | −$6.2m |
| Dividends paid | — | — | −$10.6m | — | −$23.5m | −$98.5m | −$8.6m | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $801.7m | $761.7m | $783.8m | $706.3m | $649.1m | $569.0m | $597.5m | $543.9m |
| Gross profit | $562.6m | $529.1m | $568.6m | $510.1m | $452.2m | $409.0m | $430.9m | $377.1m |
| Operating income | $129.7m | $122.1m | $146.3m | $124.7m | $48.0m | $88.8m | $109.3m | $88.1m |
| Net income | $95.0m | $91.1m | $101.6m | $87.6m | $22.5m | $35.4m | $100.7m | $77.5m |
| Diluted earnings per share | 1.37 | 1.31 | 1.44 | 1.24 | 0.32 | 0.50 | 1.36 | 1.05 |
| Cash from operations | $88.0m | $113.0m | $183.0m | $125.0m | $196.0m | $63.0m | $147.0m | $98.0m |
| Capital spending | −$29.0m | −$27.0m | −$135.0m | −$21.0m | −$23.0m | −$12.0m | −$56.0m | −$26.0m |
| Free cash flow | $59.0m | $86.0m | $48.0m | $104.0m | $173.0m | $51.0m | $91.0m | $72.0m |
| Total assets | $3.17bn | $2.99bn | $3.19bn | $3.03bn | $3.47bn | $3.52bn | $3.09bn | $3.03bn |
| Cash and short-term investments | $534.9m | $480.4m | $716.1m | $757.4m | $1.12bn | $1.28bn | $953.4m | $902.6m |
| Debt | $948.4m | $948.1m | $953.0m | $1.03bn | $1.42bn | $1.70bn | $1.38bn | $1.40bn |
| Shareholders' equity | $1.42bn | $1.30bn | $1.52bn | $1.38bn | $1.46bn | $1.33bn | $1.21bn | $1.12bn |
Financial ratios
Data as of 29 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 71.6% | 69.8% | 68.3% | 61.7% | 68.4% | 64.4% |
| Operating margin | 17.5% | 14.9% | 13.0% | 2.8% | 7.4% | 6.1% |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% |
| Return on equity | 16.3% | 34.5% | 28.2% | 1.0% | 3.0% | 1.1% |
| Return on assets | 7.7% | 13.5% | 8.0% | 0.2% | 0.8% | 0.4% |
| Free cash flow yield | 8.1% | 5.6% | 2.4% | 3.0% | 0.6% | 2.9% |
| Revenue growth | 30.7% | 22.1% | 30.0% | 18.8% | 21.5% | 22.5% |
| Earnings growth | -40.9% | 102.8% | 4384.8% | -72.6% | 147.1% | -41.4% |
| Current ratio | 2.78x | 3.54x | 3.47x | 3.56x | 5.81x | 6.01x |
| Debt to equity | 0.63x | 1.14x | 1.94x | 2.95x | 2.29x | 1.75x |
| Equity ratio | 47.5% | 39.2% | 28.3% | 21.2% | 27.2% | 32.2% |
| Interest coverage | 5.94x | 7.23x | 6.08x | 1.01x | 1.32x | 1.14x |
| R&D as a share of sales | 11.1% | 10.6% | 12.1% | 13.8% | 14.6% | 16.2% |
| Buybacks as a share of market value | 4.6% | -6.0% | 0.2% | -0.3% | -5.9% | -3.2% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 27.5% | 24.5% | 26.2% |
| Operating income | 135.0% | 53.9% | — |
| Net income | 277.3% | 105.2% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 70.8% | 68.8% | 68.3% | 67.0% |
| Operating margin | 16.4% | 13.4% | 12.0% | 9.7% |
| Net margin | 13.9% | 11.3% | 9.2% | 6.4% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 81.3 | 46.2 | 73.5 | — | — | — | — | — | -149.8 | -74.9 |
| Price to sales | 7.4 | 9.3 | 8.9 | 15.8 | 16.9 | 18.6 | 14.8 | 8.6 | 8.7 | 5.9 |
Market value over time
31 Oct 2016 to 28 Sept 2026, in USD
$2.13bn$9.24bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 14% | 19% | -27% | 15% | 8% | 37% | 136% | 5% | 83% | 2% |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.